Clinical Trial Management During COVID-19

Clinical Trial Management During COVID-19

COVID-19:Clinical Trial Management During the Pandemic MAY 2020 Jyotsana Chaudhary, MSc, Jatin Gupta, MSc and Sukanya Saha, MSc   Note: Given that the situation is continually evolving, the thoughts and opinions are formulated to keep the current situation in mind....
COVID-19 The Impact on Biopharmaceutical Companies

COVID-19 The Impact on Biopharmaceutical Companies

COVID-19: The Impact on Biopharmaceutical Companies MARCH 2020 Jyotsana Chaudhary, Jatin Gupta and Dr. Ashima Sharma   Note: The COVID-19 situation is continually evolving; the thoughts and opinions expressed here were formulated based on the situation as of...
Could TMB be a Predictor of Immunotherapy Response in NSCLC?

Could TMB be a Predictor of Immunotherapy Response in NSCLC?

By: Shweta Srivastava and Anil Sharma Tumor mutational burden (TMB (the number of mutations per megabase of DNA (mut/Mb)) can be a predictor of response for single-agent immunotherapy, but it has failed to demonstrate any correlation with response when immunotherapy...